← Eichor
Condition: Spinal Muscular Atrophy Type 2 Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Spinal Muscular Atrophy Type 2

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
Phase N/A · 1 location(s) · xCures · NCT06539169
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Phase 2 · 25 location(s) · Scholar Rock, Inc. · NCT07047144
UK SMA Patient Registry
Phase N/A · 1 location(s) · Newcastle University · NCT04292574
Study of Safety, Tolerability and Efficacy of GB221 in Infants With Spinal Muscular Atrophy Type 1
Phase 1/Phase 2 · 1 location(s) · Gemma Biotherapeutics · NCT07070999
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Phase N/A · 2 location(s) · Sanford Health · NCT01793168
Safety and Efficacy Evaluation of GC101 Gene Therapy Via Intrathecal (IT) Injectionin the Treatment of Patients With Typ
Phase 3 · 7 location(s) · GeneCradle Inc · NCT06971094
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
NA · 1 location(s) · Centre Hospitalier Universitaire de Liege · NCT07136844
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
NA · 1 location(s) · University of Missouri-Columbia · NCT07478172
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.